Eczema drug APG777 tested for Long-Term safety in 350 patients
Disease control
Recruiting now
This study looks at the long-term safety and effectiveness of APG777 in adults with moderate-to-severe eczema who have already completed treatment with the drug in an earlier study. About 350 participants will receive extended treatment and be monitored for side effects and skin …
Phase: PHASE2 • Sponsor: Apogee Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:53 UTC